Gilead Sciences, Inc. (ETR: GIS)
Germany
· Delayed Price · Currency is EUR
88.94
+1.26 (1.44%)
Dec 20, 2024, 5:35 PM CET
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.55B USD in the quarter ending September 30, 2024, with 7.02% growth. This brings the company's revenue in the last twelve months to $28.30B, up 3.31% year-over-year. In the year 2023, Gilead Sciences had annual revenue of $27.12B, down -0.60%.
Revenue (ttm)
$28.30B
Revenue Growth
+3.31%
P/S Ratio
n/a
Revenue / Employee
$1.57M
Employees
18,000
Market Cap
110.75B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGilead Sciences News
- 1 day ago - Gilead Sciences Inc (GILD) to Present at J.P. Morgan Healthcare Conference - GuruFocus
- 1 day ago - Gilead Sciences to Present at Upcoming Investor Conference - Wallstreet:Online
- 1 day ago - Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
- 2 days ago - (GILD) - Analyzing Gilead Sciences's Short Interest - Benzinga
- 2 days ago - Gilead raises Assembly Bio stake to ~30% - Seeking Alpha
- 2 days ago - Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - Wallstreet:Online
- 3 days ago - Lightning Round: Uber is attractive at these levels, says Jim Cramer - CNBC
- 3 days ago - Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus